Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PPIA | P62937 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17845602 | 0.84 | KDM4E (0.44) | KDM4ETRPA1ROCK2NPC1RAB9A | |
| SCHEMBL17845497 | 0.82 | KDM4E (0.43) | KDM4ETRPA1ROCK2NPC1RAB9A | |
| SCHEMBL17845575 | 0.82 | KDM4E (0.43) | KDM4ETRPA1ROCK2NPC1RAB9A | |
| SCHEMBL6288896 | 0.80 | DDB1 (0.47) | MEN1KMT2A | |
| SCHEMBL14368035 | 0.78 | SMN1; SMN2 (0.46) | RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5680102 | 0.75 | KCNH3 (0.46) | MEN1KMT2AGAA | |
| SCHEMBL11487199 | 0.74 | GAA (0.40) | TRPA1MAOBGAASMN1; SMN2 | |
| SCHEMBL7039605 | 0.73 | DDB1 (0.55) | ROCK2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19518920 | 0.72 | — | — | |
| SCHEMBL12270219 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557117-B2 | 4-oxoimidazolidine-2-spiropiperidine derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-07-07 | — | — | US | disclosed |
| EP-1420020-B1 | 4-OXOIMIDAZOLIDINE-2-SPIROPIPERIDINE DERIVATIVE | BANYU PHARMA CO LTD (JP) | 2008-05-28 | — | — | EP | disclosed |
| US-20070078153-A1 | 4-Oxoimidazolidine-2-spiropiperidine derivatives | MSD K.K. (JP) | 2007-04-05 | — | — | US | disclosed |
| US-7192964-B2 | 4-oxoimidazolidine-2-spiropiperidine derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-20050004363-A1 | 4-oxoimidazolidine-2-spiropiperidine derivatives | MSD K.K. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1420020-A1 | 4-OXOIMIDAZOLIDINE-2-SPIROPIPERIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078153-A1 | 4-Oxoimidazolidine-2-spiropiperidine derivatives | OPRL1, OPRK1, OPRD1 | KDM4E 2842/4885TRPA1 230/4885ROCK2 4562/4885 |
| US-20050004363-A1 | 4-oxoimidazolidine-2-spiropiperidine derivatives | OPRL1, OPRD1, OPRK1 | KDM4E 3028/4885TRPA1 222/4885ROCK2 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.